Fitzroy W Dawkins MD

Oncology•Malvern, PA

Director, Clinical Research, Janssen Pharmaceutical Company

Join to View Full Profile

200 Great Valley PkwyMalvern, PA 19355
Phone+1 610-240-8321

Education & Training

George Washington UniversityFellowship, Hematology and Medical Oncology, 1988 - 1991
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1984

Certifications & Licensure

DC State Medical License 1990 - 2018
American Board of Internal Medicine Internal Medicine

Clinical Trials

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) Start of enrollment: 2014 Mar 01
Terminated
Phase 3
A Study of Ruxolitinib in Pancreatic Cancer Patients Start of enrollment: 2014 Jun 01
Terminated
Phase 3
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 Dec 29
Completed
Phase 1, Phase 2
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Start of enrollment: 2016 Nov 30
ACTIVE_NOT_RECRUITING
PHASE2
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Start of enrollment: 2017 Mar 02
Completed
Phase 2
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Start of enrollment: 2017 Feb 15
Completed
Phase 1
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2018 Mar 14
COMPLETED
PHASE2
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease Start of enrollment: 2017 Apr 20
Terminated
Phase 1
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) Start of enrollment: 2017 Dec 18
COMPLETED
PHASE2
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) Start of enrollment: 2018 Aug 02
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

184 citations
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial
Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah
Blood. 2020-05-14
9 citations
Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials
Don Robinson, Ning Zhao, Fitzroy Dawkins, Ming Qi, Dennis A. Revicki
Quality of Life Research. 2013-04-16
29 citations
Screening for iron overload: Lessons from the HEmochromatosis and IRon Overload Screening (HEIRS) Study
Paul C. Adams, James C. Barton, Gordon D. McLaren, Ronald T. Acton, Mark Speechley
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 2009-11-01

Press Mentions

Forma Therapeutics : Appoints Two New Vice Presidents to Lead Key Organizational FunctionsSeptember 15th, 2020
Clinical Manifestations of Hemochromatosis in HFE C282Y Homozygotes Identified by ScreeningJuly 20th, 2019